Formycon AG (DE:FYB)
XETRA:FYB
Want to see DE:FYB full AI Analyst Report?
FYB Stock Chart & Stats
€19.82
€0.60(0.99%)
At close: 4:00 PM EST
€19.82
€0.60(0.99%)
Day’s Range― - ―
52-Week Range€15.80 - €31.30
Previous CloseN/A
Volume3.47K
Average Volume (3M)24.96K
Market Cap
€364.95M
Enterprise Value€340.12M
Total Cash (Recent Filing)€68.85M
Total Debt (Recent Filing)€9.56M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.66
Shares Outstanding17,672,928
10 Day Avg. Volume17,772
30 Day Avg. Volume24,962
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.13
Price to Sales (P/S)10.17
P/FCF Ratio-10.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€40.00Price Target Upside101.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.57
Revenue Forecast (FY)€64.70M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthFormycon's low leverage and relatively large equity base provide durable financial flexibility to fund R&D and absorb biotech cycle volatility. Even with equity declines, a well-capitalized balance sheet supports clinical programs and partner negotiations over the next 2–6 months without immediate financing pressure.
Partner-driven Business ModelRelying on partner-funded development, milestone payments, and licensing reduces required in-house commercial investment and concentrates capital on R&D. This model preserves capital efficiency, leverages partners' sales channels, and creates scalable revenue streams tied to approvals and commercialization over the medium term.
Improving Operating Cash FlowThe shift to positive operating cash flow indicates improving core cash generation from operations, a durable sign that underlying business activities may be stabilizing. If sustained, this reduces near-term funding needs and strengthens the company's ability to support ongoing clinical programs without relying solely on external capital.
Bears Say
Revenue Contraction And VolatilitySustained revenue declines and volatility reduce predictability of milestone and royalty inflows central to Formycon's partner-based model. Over 2–6 months this undermines cash visibility, complicates partner negotiations and budgeting for clinical programs, and raises execution risk for commercialization timing.
Swing To Deep LossesA rapid shift from profitable years to material losses signals inconsistent earnings power and operational risk. Persistent losses erode equity cushions, limit reinvestment capacity, and increase the likelihood of needing external financing or partner concessions if losses continue over the medium term.
Negative And Worsening Free Cash FlowDeep and worsening free cash flow reflects that operating inflows do not cover investments and cash burn. Even with a solid balance sheet, persistent negative FCF creates a structural funding risk over months ahead, potentially forcing dilutive financing, slower program pacing, or greater reliance on partner funding.
Formycon AG News
FYB FAQ
What was Formycon AG’s price range in the past 12 months?
Formycon AG lowest stock price was €15.80 and its highest was €31.30 in the past 12 months.
What is Formycon AG’s market cap?
Formycon AG’s market cap is €364.95M.
When is Formycon AG’s upcoming earnings report date?
Formycon AG’s upcoming earnings report date is Jul 01, 2026 which is in 23 days.
How were Formycon AG’s earnings last quarter?
Formycon AG released its earnings results on Apr 22, 2026. The company reported -€0.59 earnings per share for the quarter, missing the consensus estimate of -€0.19 by -€0.4.
Is Formycon AG overvalued?
According to Wall Street analysts Formycon AG’s price is currently Undervalued.
Does Formycon AG pay dividends?
Formycon AG does not currently pay dividends.
What is Formycon AG’s EPS estimate?
Formycon AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Formycon AG have?
Formycon AG has 17,672,928 shares outstanding.
What happened to Formycon AG’s price movement after its last earnings report?
Formycon AG reported an EPS of -€0.59 in its last earnings report, missing expectations of -€0.19. Following the earnings report the stock price went down -3.987%.
Which hedge fund is a major shareholder of Formycon AG?
Currently, no hedge funds are holding shares in DE:FYB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Formycon AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.19%
12-Months-Change
Fundamentals
Return on Equity
-16.02%
Trailing 12-Months
Asset Growth
-4.17%
Trailing 12-Months
Company Description
Formycon AG
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
FYB Stock 12 Month Forecast
Average Price Target
€40.00
▲(101.82% Upside)
Technical Analysis
Options Prices
Currently, No data available
---